Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.

Background: The aims of this study were to define the mRNA expression profiles of MYCN, DDX1, TrkA, and TrkC in biopsy tumor samples from 64 Brazilian patients with neuroblastomas of different risk stages and to correlate altered expression with prognostic values. Procedure: Patients were retrospect...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Blood & Cancer Vol. 56; no. 5; pp. 749 - 757
Autores principales: Souza DR, Sanabani SS, Souza AC, Odone VF, Epelman S, Bendit I, de Souza, Daniela Raguer Valadão, Sanabani, Sabri Saeed, de Souza, Ana Carolina Mamana Fernandes, Filho Odone, Vicente, Epelman, Sidnei, Bendit, Israel
Formato: research Journal Article
Publicado: Wiley-Blackwell May2011
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104570466&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104570466
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15455009
        1XL2
      jtl: Pediatric Blood & Cancer
      issn: 15455009
      maglogo: Y
    pubinfo:
      dt: May2011
      vid: 56
      iid: 5
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        104570466
        NLM21154590
        2010968440
        10.1002/pbc.22823
        NLM21154590
        104570466
      ppf: 749
      ppct: 8
      formats:
      tig:
        atl: Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
      aug:
        au:
          Souza DR
          Sanabani SS
          Souza AC
          Odone VF
          Epelman S
          Bendit I
          de Souza, Daniela Raguer Valadão
          Sanabani, Sabri Saeed
          de Souza, Ana Carolina Mamana Fernandes
          Filho Odone, Vicente
          Epelman, Sidnei
          Bendit, Israel
        affil: Laboratorio de Biologia Tumoral da Disciplina de Hematologia da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
      sug:
        subj:
          Transferases
          Genes Physiology
          Neuroblastoma
          Proteins
          Receptors, Cell Surface
          Tumor Markers, Biological
          Child
          Child, Preschool
          Female
          Infant
          Infant, Newborn
          Male
          Neoplasm Staging
          Neuroblastoma Pathology
          Prognosis
          RNA
          Retrospective Design
          Reverse Transcriptase Polymerase Chain Reaction
          Survival
          Tumor Markers, Biological Metabolism
          Human
          Child: 6-12 years
          Child, Preschool: 2-5 years
          Infant: 1-23 months
          Infant, Newborn: birth-1 month
          Female
          Male
      ab: Background: The aims of this study were to define the mRNA expression profiles of MYCN, DDX1, TrkA, and TrkC in biopsy tumor samples from 64 Brazilian patients with neuroblastomas of different risk stages and to correlate altered expression with prognostic values. Procedure: Patients were retrospectively classified into low- (n = 11), intermediate- (n = 18), and high-risk (n = 35) groups using standard criteria. The mRNA levels of the above genes were measured by quantitative real-time polymerase chain reaction. Univariate analyses were performed and survival curves were plotted by the Kaplan-Meier method. Results: Of the 64 patients, 53% were female and 62.5% were older than 18 months. The 5-year overall survival (OS) for the entire cohort was 40.3%, with inferior median OS in patients identified in the intermediate- and high-risk groups. A significant difference in OS with respect to TrkA mRNA expression was found for the high-risk group vs. either the low- or intermediate-risk groups (P < 0.01, log rank test). Within the intermediate-risk group, neuroblastoma patients with positive TrkA mRNA expression had better clinical outcomes than patients with no TrkA transcript expression (P = 0.004). Another difference in OS was only found between the intermediate- and high-risk groups (P < 0.027, log rank test). No significant correlation of mRNA expression and survival outcome could be detected for the MYCN, DDX1. Conclusions: Positive expression of TrkA mRNA may be a clinically useful addition to the current risk classification system, allowing the identification of NB tumors with favorable prognosis.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N